AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

At AstraZeneca, we believe the best way we can help patients is to focus on breakthrough science in order to uncover disease mechanisms and develop novel, targeted therapies that interact with them. This is at the heart of our purpose as a company: to push the boundaries of science to deliver life-changing medicines. We are committed to developing novel therapies that advance the science of neurodegenerative diseases and have the potential to provide a positive impact on patients around the world.

We have recently consolidated our teams working in the Innovative Medicines and Early Development Biotech Unit and in MedImmune to create a single AstraZeneca neuroscience team, led from Cambridge UK, covering both small molecules and biologics. With a rich heritage and a research and development focus on specific aspects of neurodegenerative diseases, analgesia and psychiatry, we continue to push the boundaries of science in neuroscience in collaboration with other innovative partners across industry and academia.

« Go Back

Supporting Publication
Organised by
  • Lancet Neurology
  • Elsevier
Silver Sponsor